Elevated miR-33a and miR-224 in steatotic chronic hepatitis C liver biopsies

Gabor Lendvai, Katalin Jármay, Gizella Karácsony, Tünde Halász, Ilona Kovalszky, Kornélia Baghy, Tibor Wittmann, Zsuzsa Schaff, András Kiss

AIM: To assess the expression of selected microRNAs (miRNA) in hepatitis C, steatotic hepatitis C, noninfected steatotic and normal liver tissues.

METHODS: The relative expression levels of miR-21, miR-33a, miR-96, miR-122, miR-125b, miR-221 and miR-224 were determined in 76 RNA samples isolated from 18 non-steatotic and 28 steatotic chronic hepatitis C (CHC and CHC-Steatosis, respectively) cases, 18 non-infected, steatotic liver biopsies of metabolic origin (Steatosis) and 12 normal formalin-fixed paraffin-embedded liver tissues using TaqMan MicroRNA Assays. All CHC biopsy samples were obtained prior to initiating therapy. Patients’ serum biochemical values, which included glucose, triglyceride, cholesterol, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl-transferase (GGT), alkaline phosphatase (AP), were obtained and correlated with relative miRNA expression.

RESULTS: When compared with control non-infected liver samples, miR-122 and miR-221 levels were reduced in CHC-Steatosis (P < 0.03) and in CHC, CHC-Steatosis and Steatosis (P < 0.01). Alternatively, the expression of miR-33a and miR-224 were elevated in CHC-Steatosis and Steatosis in comparison to control tissue (P < 0.01). The levels of miR-33a and miR-224 in CHC-Steatosis (P < 0.02) and miR-224 in Steatosis (P < 0.001) were increased in comparison to CHC samples. By contrast, the expression of miR-21 did not differ statistically between diseased and normal liver samples. Levels of miR-33a correlated negatively with serum AST and AP levels in Steatosis as well as with necroinflammatory grade in CHC, whereas miR-21 correlated positively with AST in Steatosis and displayed negative correlation with triglyceride level in CHC-Steatosis. In contrast, miRNA levels were not correlated with ALT, GGT, cholesterol levels or fibrosis stage.

CONCLUSION: Differences in miRNA expression were observed between CHC and steatotic CHC, CHC and steatotic liver, but not between steatotic CHC and steatotic liver of metabolic origin.

Key words: Chronic hepatitis C; Steatosis; MicroRNA; Expression; miR-33a; miR-224

Core tip: Chronic hepatitis C (CHC) and steatosis are
liver diseases that can progress into hepatocellular carcinoma. In the current study, differences were found in expression of selected microRNAs in biopsy samples of steatotic liver, CHC-infected, and steatotic CHC-infected liver, compared to control samples. Interestingly, levels of miR-224, which are increased in hepatocellular carcinoma, were elevated in both types of steatotic liver when compared with normal or CHC-infected only liver tissues, and may be an indicator of a precancerous state.

INTRODUCTION

Hepatitis C virus (HCV) infection is a significant health care problem worldwide. It is estimated that approximately 170 million people are infected with HCV[5] and 3% of the world’s population is chronically infected with this virus[5]. Approximately 70% to 80% of acute infected cases will develop into chronic hepatitis C (CHC) due to failed elimination of the virus; nearly 20% of CHC patients develop cirrhosis and 20% of the cirrhotic cases further progress to hepatocellular carcinoma (HCC)[5]. Treatment options for CHC include combination of pegylated interferon and ribavirin, however, the virus still fails to clear in a significant proportion of treated patients[6], which contributes to the numerous liver transplantations worldwide. A new triple therapy regimen with protease inhibitors holds great promise as clinical trials have ended with a significantly improved percent of patients reaching a sustained viral response[7].

In addition to cirrhosis, hepatic steatosis is also frequently observed in CHC in approximately 40%-86% of CHC patients depending on the viral genotype[8-9]. In cultured Huh7 cells, for example, HCV genotype 3a core protein results in the highest level of triglyceride accumulation[10,11]. The prevalence of steatosis in HCV-infected patients is two-folds higher than that observed in hepatitis B virus-infected patients, which demonstrates a correlation between CHC and nonalcoholic fatty liver disease (NAFLD)[12,13]. Hepatic steatosis occurs when fatty acids, delivered either from the circulation or synthesized de novo by the liver, exceed the liver’s capacity to metabolize fat by means of β-oxidation or to secrete fat as very-low-density lipoproteins (VLDL). This imbalance between delivery of fat and its subsequent secretion or metabolism leads to accumulation of lipid droplets containing triglycerides and cholesteryl esters, predominantly in hepatocytes[13]. In NAFLD, the development of steatosis is linked to obesity and metabolic disorders such as hyperlipidemia, insulin resistance and diabetes[14,15]. In addition, steatosis is associated with higher alanine aminotransferase (ALT) levels[16].

MicroRNAs (miRNA) are short RNA molecules considered to negatively modulate gene expression through fine-tuning gene expression involved predominantly in development, immunity, differentiation and homeostasis[17]. miRNAs act at the posttranscriptional level and induce translational arrest by binding to the 3’ untranslated region (UTR) of messenger RNAs, leading to a reduction or blockage of protein synthesis[18]. In comparison to normal homeostatic conditions, altered miRNA expression has been reported in cancers[19] and in several other pathologies including liver diseases[20,21]. Moreover, a few miRNAs are already suggested to be potential biomarkers for HCC and chronic hepatitis B infection[22-24].

In the present study, CHC-infected, steatotic CHC-infected and NAFLD-based steatotic liver biopsies were compared to non-infected, normal liver samples to assay differences in the expression of selected miRNAs that previously have been associated with fibrosis (miR-21, miR-221), fat metabolism (miR-33a, miR-122) and hepatocarcinogenesis (miR-21, miR-122, miR-221, miR-224)[24-27].

MATERIALS AND METHODS

Patients

A total of 64 patients were enrolled in this study, from which 46 CHC-infected patients (genotype 1/b) were hospitalized at the 1st Department of Medicine at the University of Szeged. These patients were divided into two groups (CHC or CHC-Steatosis) according to the presence of steatosis in the liver samples, as diagnosed by experienced pathologists. Accordingly, 18 patients with CHC but without any apparent signs of steatosis were included in the CHC group, whereas 28 CHC patients having either mild or severe steatosis were included in the CHC-Steatosis group (Table 1). An additional 18 patients with metabolic steatosis of varying degrees but no HCV infection were selected for the Steatosis group from the archives of the 2nd Department of Pathology at Semmelweis University. Twelve non-infected, normal liver samples served as controls and were obtained from deceased patients after organ donation, just prior to ligation of the abdominal aorta and reperfusion. In addition, the following serum biochemical values were detected and recorded at the time of biopsy: glucose, triglyceride, cholesterol, ALT, aspartate aminotransferase (AST), gamma-glutamyl-transferase (GGT), alkaline phosphatase (AP). The selected samples were analysed retrospectively with permission obtained from the local Ethical Committee based on the ethical guidelines of the 1975 Declaration of Helsinki. Antiviral treatment had not been initiated before obtaining the liver biopsy samples from the CHC patients.

Histology

Liver samples were processed according to routine pathology procedures. Briefly, liver tissues were submerged...
### RESULTS

#### Differences in miRNA expression

Deregulated miRNA expression was observed in the diseased liver samples as compared with normal control liver samples. Decreased levels of miR-221 were found in CHC, CHC-Steatosis and Steatosis samples (1/5-fold, \( P < 0.0001 \) and 7-fold, \( P < 0.0003 \); respectively) and reduced expression of miR-122 was detected in CHC-Steatosis samples (1/11-fold, \( P < 0.0008 \); respectively) and Steatosis samples (1/8-fold, \( P < 0.0001 \)). Elevated levels of miR-33a and miR-224 were found in CHC-Steatosis (5-fold, \( P < 0.0001 \) and 5-fold, \( P < 0.0003 \); respectively) and Steatosis (4-fold, \( P < 0.01 \) and 7-fold, \( P < 0.0001 \); respectively) samples in comparison with control normal liver samples. The expression of miR-21 was not statistically different between the diseased and normal liver samples. Elevated levels of miR-33a and miR-224 were observed in CHC-Steatosis samples compared with CHC samples (2-fold, \( P < 0.02 \) and 4-fold, \( P < 0.003 \); respectively). Furthermore, increased miR-224 expression was found in 10% neutral buffered formalin (in phosphate-buffered saline, pH 7.0) immediately after removal and fixed for 24 h at room temperature. Following dehydration in an ethanol series and xylene, the formalin-fixed samples were embedded in paraffin (FFPE samples). Paraffin-embedded samples were cut into 3 to 5 \( \mu \)m thick sections and staining with HE as well as with picrosyrus red for highlight connective tissue. Histological grade and stage were determined using the Ishak scoring system after a staining with picrosyrus red for highlight connective tissue.

### Table 1  Clinical background of patients enrolled in this study

<table>
<thead>
<tr>
<th></th>
<th>CHC</th>
<th>CHC-steatosis</th>
<th>Steatosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr, mean ± SD)</td>
<td>42.1 ± 13.2</td>
<td>39.3 ± 14.9</td>
<td>47 ± 11</td>
</tr>
<tr>
<td>Gender</td>
<td>10 males, 8 females</td>
<td>17 males, 9 males, 22 females</td>
<td>9 females</td>
</tr>
<tr>
<td>Grade(^1)</td>
<td>G1-1, G1-0</td>
<td>G2-1, G3-3, G4-1, G5-4</td>
<td>-</td>
</tr>
<tr>
<td>Stage(^1)</td>
<td>G1-1</td>
<td>G1-1</td>
<td>-</td>
</tr>
<tr>
<td>Steatosis grade(^1)</td>
<td>S0-0</td>
<td>S0-0</td>
<td>S0-0</td>
</tr>
<tr>
<td>AST (U/L, mean ± SD)</td>
<td>54 ± 26 (^1)</td>
<td>69 ± 58</td>
<td>54 ± 22</td>
</tr>
<tr>
<td>ALT (U/L, mean ± SD)</td>
<td>79 ± 39</td>
<td>114 ± 91</td>
<td>95 ± 43</td>
</tr>
<tr>
<td>GGT (U/L, mean ± SD)</td>
<td>39 ± 39</td>
<td>83 ± 123</td>
<td>219 ± 185</td>
</tr>
<tr>
<td>AP (U/L, mean ± SD)</td>
<td>119 ± 74</td>
<td>124 ± 100</td>
<td>239 ± 167</td>
</tr>
<tr>
<td>Cholesterol (mmol/L, mean ± SD)</td>
<td>4.59 ± 0.84</td>
<td>3.30 ± 1.93</td>
<td>6.23 ± 1.24</td>
</tr>
<tr>
<td>Triglyceride (mmol/L, mean ± SD)</td>
<td>0.96 ± 0.51</td>
<td>0.94 ± 0.68</td>
<td>2.31 ± 1.46</td>
</tr>
</tbody>
</table>

\(^1\)Number of cases for each grade and stage are given. The histologic grade and stage were determined according to the Ishak scoring system; \(^1\)The numerical data are presented as the average ± SD. ALT: Alanine transaminase; AP: Alkaline phosphatase; AST: Aspartate transaminase; CHC: Chronic hepatitis C; GGT: Gamma-glutamyl-transferase.

#### Statistical analysis

The normalized relative expression data were analyzed with a nonparametric Kruskal-Wallis ANOVA and median test using STATISTICA software, version 9.1 (StatSoft Inc., Tulsa, OK, United States). Correlation analysis between miRNA expression and histologic grades or serum biochemical values of patients was performed with a nonparametric Spearman rank correlation using GraphPad PRISM software, version 5.01 (GraphPad Software Inc, La Jolla, CA, United States). A \( P \)-value of 0.05 was set as the threshold for statistical significance.
in Steatosis samples compared with CHC samples (five-fold, \( P < 0.001 \)) (Figure 1).

**Correlation between miRNA expression, serum biochemical values and histology grade**

miR-33a levels showed a negative correlation with AP and AST values in Steatosis samples and also with the histology grade in CHC samples. In contrast, the expression of miR-21 correlated positively with AST levels in Steatosis samples but showed a negative correlation with triglyceride levels in CHC-Steatosis samples (Table 2). The analyzed miRNA levels displayed no correlation with ALT, GGT, cholesterol levels or fibrosis stage in the liver disease samples. In addition, a correlation between miRNA expression and steatosis grade was not observed in either the CHC-Steatosis or the Steatosis group.

**DISCUSSION**

In HCV infection, it is implied that the pathogenesis of steatosis is linked to both metabolic and viral factors\(^{12,13,31-33} \). HCV has been shown to contribute to steatosis in many ways. The HCV core protein facilitates the accumulation of triglyceride-rich droplets through impaired lipid oxidation and inhibits microsomal triglyceride transfer protein activity, which ultimately reduces the assembly and secretion of apolipoprotein B-containing VLDL\(^{11,34} \). In addition to perturbed fat metabolism, fat is reported to be required for the assembly of new HCVs\(^{15} \). In addition, HCV forms
lipoviral particles with host lipoproteins and these complexes are enriched in triglyceride, cholesterol, and several apolipoproteins. These structures, which resemble VLDLs, help the viruses avoid detection by the immune system[35]. Furthermore, HCV viral proteins (core, NS2 and NS4B) may contribute to transcriptional activation of lipogenic genes in hepatocytes, such as SREBPs and PPAR-\(\alpha\),\(\gamma\), contributing to fat accumulation by elevating cholesterol biosynthesis and import from the blood and by deregulating fatty acid \(\beta\)-oxidation and insulin sensitivity, respectively[36].

It has been shown that low sterol conditions allow liver cells to protect themselves from additional sterol loss. SREBP-2, a transcription factor, is induced by low intracellular cholesterol level and activates lipogenic genes[37]. This also induces production of miR-33a, which is co-expressed with SREBP-2 from intron 16 of the SREBP-2 gene. miR-33a protects cells from sterol loss by downregulating the ABCA1 transporter needed for efflux of cholesterol to generate high density lipoprotein (HDL)[38]. It has also been demonstrated that activation of miR-33a results in reduced insulin signalling, cellular \(\beta\)-oxidation and cell proliferation by inhibiting CDK6 and cyclinD1, leading to cell cycle arrest in G1 phase[39]. Therefore, antagonism of miR-33a has been proposed as a therapeutic strategy for treating metabolic syndrome and NAFLD[39].

Results of the present study showing elevated miR-33a levels in CHC-Steatosis samples as compared with CHC, and also in CHC-Steatosis and Steatosis samples when compared with normal liver samples are in accordance with previous findings. These findings indicate an elevated fat retention in samples having hepatic steatosis. The lack of differences between CHC-Steatosis and Steatosis intriguingly suggests that the combination of HCV and steatosis does not further increase the level of miR-33a. Moreover, miR-33a did not correlate with the steatosis stage either in the CHC-Steatosis or Steatosis sample groups.

In contrast, the expression level of miR-122 did not differ between the examined liver disease groups and decreased expression was observed in CHC-Steatosis samples as compared with control liver samples. As in the case of miR-33a, the regulatory function of miR-122 is also connected to fat metabolism. It may act indirectly on lipid metabolism as silencing of miR-122 is reported to decrease cholesterol level, VLDL and HDL fractions as well as fat accumulation in the liver; a target gene involved in fat metabolism, however, is yet to be identified[40]. Therefore, the role of miR-122 in lipid metabolism and the observed decreased expression of this miRNA in CHC-Steatosis samples appears contradictory. However, miR-122 is known to be a liver-enriched miRNA, composing 70% of total miRNAs in normal hepatocytes[41]. Upon liver injury, when normal hepatocytic activity is compromised[42], miR-122 levels have been shown to be decreased. For example, miR-122 expression is downregulated in NAFLD[36,42], HCV-infected cases[43] and HCC[44]. Accordingly, the observed reduction in miR-122 expression further suggests that it likely results from reduced hepatocyte activity due to liver injury.

In HCV infection, miR-122 has also been shown to bind to HCV RNA at two sites of the 5' UTR, which promotes replication and stimulates translation in vivo[45]. In vivo, however, it is more likely that the role of miR-122 binding to the 5' UTR is to protect HCV RNA from exonuclease degradation, as a correlation between miR-122 expression and intrahepatic or serum viral load has not been identified in vivo[46]. Similarly, our results did not demonstrate increased levels of miR-122 in CHC and CHC-Steatosis samples in the presence of HCV. Furthermore, reduced miR-122 expression could also indicate a disease state preceding cancer, as the loss of miR-122 is a frequent finding in HCC and correlates with migration, invasion and in vivo tumorigenesis[47].

It is known that downregulation of a miRNA may upregulate target oncogenes, thus promoting tumor growth due to stimulation of proliferation. In contrast, upregulation of a miRNA may prevent expression of tumor suppressor genes, which normally function to inhibit progression of the cell cycle[48]. In hepatocarcinogenesis, gradual increases in expression of miR-21, miR-221 and miR-224 are reported to occur as the liver transitions from normal liver through cirrhosis to fully developed HCC[49]. Therefore, we aimed to investigate whether CHC and steatosis - diseases that eventually lead to HCC - would show an elevated expression of these miRNAs. It was interesting to find that the observed levels were quite different: miR-224 was upregulated, miR-221 was downregulated and miR-21 showed no change.

miR-224 is reported to be an oncomiR that promotes proliferation, migration and invasion in HCC through activation of AKT signaling, and has been shown to function in liver carcinogenesis and progression[41]. Therefore, the observed elevation of miR-224 levels in CHC-Steatosis and Steatosis samples compared with both CHC and normal liver samples may indicate that steatotic CHC and steatosis could be disease states with molecular changes characteristic of a precancerous stage. It has been suggested that an imbalance in the normal miRNA pattern leading to disease onset can be measured long before the onset of a cancer[40]. miR-221, also a known oncomiR, was found to be elevated in HCC.

---

Table 2 Non-parametric Spearman's rank correlation between serum biochemical values, histology grade and miRNA expression levels

<table>
<thead>
<tr>
<th>Sample group</th>
<th>Histologic or serum parameter</th>
<th>Correlating miRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHC</td>
<td>Grade</td>
<td>miR-33a ((r &lt; 0.006; r = -0.7))</td>
</tr>
<tr>
<td>CHC-Steatosis</td>
<td>Triglyceride</td>
<td>miR-21 ((r &lt; 0.05; r = -0.4))</td>
</tr>
<tr>
<td>Steatosis</td>
<td>AST</td>
<td>miR-21 ((r &lt; 0.004; r = 0.8))</td>
</tr>
<tr>
<td></td>
<td>AP</td>
<td>miR-33a ((r &lt; 0.05; r = -0.7))</td>
</tr>
</tbody>
</table>

**AP**: Alkaline phosphatase; **AST**: Aspartate transaminase; **CHC**: Chronic hepatitis C; **miRNA**: MicroRNA.
and in precancerous stages of human cirrhotic CHC and a nonalcoholic steatohepatitis mouse model[27], miR-221 primarily targets tumor suppressors that inhibit the cell cycle. In contrast to the observed elevation in miR-224 levels, the reduced expression of miR-221 in our liver disease samples may indicate that miR-221 is not turned on as early in CHC, CHC-Steatosis or NAFLD, although increased miR-221 expression has been observed in choline and folate-deficient NAFLD animal models[46]. The oncomiR miR-21 has been implicated in promoting cell proliferation, migration, invasion and tumor growth by inducing epithelial-mesenchymal transition through the AKT/ERK pathway[43]. miR-21 is often overexpressed in cancers, including HCC[27], and in the regenerating liver[28]. Upregulation of miR-21 is also reported to be present in human liver biopsies of obese patients and rats that were fed high-fat diets. It has been shown that unsaturated fatty acids upregulate miR-21 levels, and this in turn downregulates PTEN and causes fatty acids to trigger steatosis[49]. In contrast, our results did not reveal elevated expression of miR-21 in the examined liver disease groups. Variations in individual miR-21 levels have already been reported in CHC patients[28] and downregulation of miR-21 has also been found in obese mice and in steatotic cells[47,48].

Interestingly, our analysis revealed negative correlations of miR-33a expression with AST and AP levels and inflammation. A negative correlation was also observed when miR-21 levels were compared with triglyceride levels. Thus, it appears that fat metabolism may be influenced by the extent of necroinflammation in CHC and Steatosis samples, most likely through the release of miR-33a from damaged liver cells into serum. In addition, high fat is capable of influencing miR-21-regulated proliferation where it may affect liver regeneration in CHC-Steatosis. Nevertheless, necroinflammation seemed to correlate with the level of miR-21 in Steatosis samples, thus contributing to the stimulation of proliferation. In support of this finding, AST levels have been reported to correlate with miR-21 in a CCl4 mouse model for fibrosis[28].

In conclusion, deregulated expression of selected miRNAs (with the exception of miR-21) was observed in the CHC, CHC-Steatosis and Steatosis groups. The levels of miR-33a and miR-224 were increased in association with steatosis when compared with CHC-infected and normal livers. Nevertheless, CHC, as a dual effect together with steatosis, might also have contributed to the elevation of these miRNAs in the CHC-Steatosis group, in which the expression of miR-122 might be reduced for similar reasons. In contrast, the observed decrease in the expression of miR-221 was independent of etiology. Intriguingly, no difference in the expression of selected miRNAs was found between CHC-Steatosis samples and steatotic liver samples of metabolic origin, indicating that biological changes caused by steatosis are more profound at the molecular and cellular level than that of CHC alone; however further studies are warranted on this topic.

REFERENCES


**P-Reviewer:** Osna NA  **S-Editor:** Ma YJ  **L-Editor:** A  **E-Editor:** Liu XM